Targets for Ibrutinib Beyond B Cell Malignancies

E-ISSN： 1365-3083|82|3|208-217

ISSN： 0300-9475

Source： SCANDINAVIAN JOURNAL OF IMMUNOLOGY (ELECTRONIC), Vol.82, Iss.3, 2015-09, pp. : 208-217

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting Bruton's tyrosine kinase with ibrutinib in B‐cell malignancies

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 5, 2015-05 ,pp. : 455-468

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ibrutinib‐associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 1, 2015-07 ,pp. : 131-134

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma

Case Reports in Oncology, Vol. 10, Iss. 1, 2017-01 ,pp. : 127-129

Karger

Access to resources Recommend Favorite

The Incidence and Risk Factors of Infusion-Related Reactions to Rituximab for Treating B Cell Malignancies in a Single Tertiary Hospital

Oncology, Vol. 86, Iss. 3, 2014-01 ,pp. : 127-134

Karger

Access to resources Recommend Favorite

CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies

Oncology Research and Treatment, Vol. 38, Iss. 12, 2015-0 ,pp. : 683-690

Karger

Access to resources Recommend Favorite